
Opinion|Videos|April 15, 2024
Monitoring and Mitigating Adverse Events
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































